Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361173 | 0.95 | GHSR (0.84) | GHSR | |
| SCHEMBL13222031 | 0.95 | GHSR (1.00) | GHSR | |
| SCHEMBL3047866 | 0.95 | GHSR (0.84) | GHSR | |
| SCHEMBL29405784 | 0.95 | GHSR (0.84) | GHSR | |
| SCHEMBL17264095 | 0.95 | GHSR (0.84) | GHSR | |
| SCHEMBL10039210 | 0.95 | GHSR (0.84) | GHSR | |
| SCHEMBL19133141 | 0.93 | GHSR (0.93) | GHSR | |
| SCHEMBL13222102 | 0.92 | GHSR (0.91) | GHSR | |
| SCHEMBL13221999 | 0.92 | GHSR (0.83) | GHSR | |
| SCHEMBL13222050 | 0.92 | GHSR (0.85) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022251219-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCLE LOSS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-01 | — | — | WO | claimed |
| US-20220370410-A1 | Compositions and Methods for Treating Muscle Loss | US GOV VETERANS AFFAIRS (US) | 2022-11-24 | — | — | US | claimed |
| US-12569476-B2 | Piperidine urea derivatives for use as inotropic agents | HELSINN HEALTHCARE SA (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20250387340-A1 | COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-12-25 | — | — | US | disclosed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250235442-A1 | Piperidine Urea Derivatives for Use as Inotropic Agents | HELSINN HEALTHCARE SA (CH) | 2025-07-24 | — | — | US | disclosed |
| US-20250205216-A2 | Piperidine Urea Derivatives for Use as Inotropic Agents | HELSINN HEALTHCARE SA (CH) | 2025-06-26 | — | — | US | disclosed |
| US-20240277688-A1 | Piperidine Urea Derivatives for Use as Inotropic Agents | HELSINN HEALTHCARE SA (CH) | 2024-08-22 | — | — | US | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| CN-117412750-A | Piperidine urea derivatives as force-modifying agents | 赫尔森保健股份公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2022251219-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCLE LOSS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220370410-A1 | Compositions and Methods for Treating Muscle Loss | US GOV VETERANS AFFAIRS (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022191184-A1 | GHRELIN RECEPTOR SENSITIVITY-ENHANCING AGENT, GHRELIN RECEPTOR SENSITIVITY-ENHANCING COMPOSITION, AND GHRELIN RECEPTOR ACTIVATION METHOD | 国立大学法人九州大学 | 2022-09-15 | — | — | WO | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235442-A1 | Piperidine Urea Derivatives for Use as Inotropic Agents | ATP2A1, ATP2A3, ATP2A2 | GHSR 3280/4885 |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | GHSR 3703/4885 |
| US-12569476-B2 | Piperidine urea derivatives for use as inotropic agents | ATP2A2, ATP2A1, ATP2A3 | GHSR 1719/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | GHSR 365/4885 |
| US-20240277688-A1 | Piperidine Urea Derivatives for Use as Inotropic Agents | ATP2A1, ATP2A3, ATP2A2 | GHSR 3306/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | GHSR 365/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | GHSR 3727/4885 |
| US-20250205216-A2 | Piperidine Urea Derivatives for Use as Inotropic Agents | ATP2A1, ATP2A3, ATP2A2 | GHSR 3210/4885 |
| US-20250387340-A1 | COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPR1, NPPA, SLC7A1 | GHSR 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.